Aligos Therapeutics, Inc. Common Stock

ALGSNASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
5.74 USD
↘ 0.01 (0.17%)AT CLOSE (11:59 AM EDT)
5.73
↘ 0.01 (0.21%)
POST MARKET (AS OF 05:00 PM EDT)
Post Market
AS OF 05:00 PM EDT
5.73
↘ 0.01 (0.21%)
🟢Market: OPEN

ALGS is currently priced at $5.88. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place ALGS at a fair price relative to peers.

Technical & fundamental data as of Jul 17, 2026.

Open?$5.70
High?$5.85
Low?$5.60
Prev. Close?$5.75
Volume?47.2K
Avg. Volume?223.2K
VWAP?$5.73
Rel. Volume?0.21x
Bid / Ask
Bid?$4.52 × 100
Ask?$6.50 × 100
Spread?$1.98
Midpoint?$5.51
Valuation & Ratios
Market Cap?35.6M
Shares Out?5.4M
Float?4.8M
Float %?89.2%
P/E Ratio?N/A
P/B Ratio?1.12
EPS?-$14.60
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Themes
Biotech - Drug Development›Infectious Disease & VaccinesBiotech - Drug Development›Metabolic & Cardiometabolic
Employees
82
Market Cap
35.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.aligos.com
Listed
2020-10-16
Address
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, CA 94080
Phone: (800) 466-6059
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
35
Short Sent.?
59
Piotroski F-Score?2/9Weak
Altman Z-Score?-17.92Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.30%High
Short Interest?543.3K
Days to Cover?7.9
Free Float4.8M
Avg Daily Volume68.4K
Settlement Date2026-06-30
Financial Health
Current Ratio?2.55Strong
Quick Ratio?2.55Strong
Cash Ratio?1.29Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
94
1.12CHEAP▾
P/S?
Peers
100
S&P
15
7.56HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.1CHEAP▾
EV/Sales?
Peers
100
S&P
88
1.21CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-284.1%WEAK▾
ROA?
S&P
3
-139.9%WEAK▾
Cash Flow & Enterprise
FCF?$-85185000
Enterprise Value?$5.7M
Fundamentals ratios updated end of day
MarketsMoversWatchlist